If I’d invested £1,000 in AstraZeneca shares five years ago, here’s what I’d have now

AstraZeneca shares have been the FTSE 100’s standout star over the past five years. But how much would I have made buying this stock five years ago?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At present, the total value of the UK’s FTSE 100 index is almost £2.03trn. Yet just 10 mega-cap firms account for £1trn (49.1%) of this total. The biggest Footsie company today is pharmaceutical giant AstraZeneca (LSE: AZN), whose shares have soared in recent years.

The rise and rise of AstraZeneca shares

On Friday, the AstraZeneca share price closed at 11,746p, down 50p. This values the UK’s biggest healthcare company at £180.8bn. Therefore, this business alone accounts for 8.9% of the entire FTSE 100.

Why is AstraZeneca worth so much? Because its shares have been surging for years. Here’s how the share price has performed over eight periods:

One week-2.2%
One month+5.2%
Three months+10.4%
Six months+16.0%
One year+11.2%
Two years+56.5%
Three years+43.5%
Five years+135.3%

Remarkably, the stock has produced positive returns over all periods ranging from one month to five years. The only fall was a modest decline last week.

Thanks to this outstanding performance, the shares have thrashed the FTSE 100 (+4%) over the past half-decade. In fact, this stock is the Footsie’s #1 performer over the last five years.

However, the above returns exclude cash dividends, which would add a few percentage points a year to these figures.

Investing £1,000 five years ago

To answer the question in my title: how much would I have today had I bought £1,000 of AstraZeneca stock exactly five years ago?

The shares’ 135.3% capital gain over 60 months would have turned my original £1,000 into £2,353 today. That works out at a compound annual growth rate of 18.7% a year. Nice.

However, AstraZeneca shares pay out regular dividends in US dollars. Here are the last five years’ payouts:

Financial year-endTotal dividendsIn £s today
31/12/2022$2.90£2.31
31/12/2021$2.87£2.29
31/12/2020$2.80£2.23
31/12/2019$2.80£2.23
31/12/2018$2.80£2.23
Total$14.17£11.30

My table shows total dividends per share paid out over the past five years add up to £11.30.

The original £1,000 investment would have bought 20 AstraZeneca shares at just under £50 each in 2018. Thus, my total dividends would come to £11.30 times 20, which is £225.90.

Hence, my total return (capital gain plus cash dividends) from AstraZeneca stock over five years would be £2,353 plus £225.90, which equals £2,578.90.

That’s a total return of 157.9%, which works out at a compound annual growth rate of almost 20.9% a year. How I’d love to have earned similar returns from every stock in my portfolio.

What about the future?

Investors who jumped aboard the AstraZeneca bandwagon have seen the company’s revenues more than double over the past five years, leaping from $22.1bn in 2018 to $44.4bn in 2022.

Of course, there’s no guarantee that the rapid growth in both revenues and the share price will continue for another five years. But analysts highly rate CEO Pascal Soriot (appointed back in October 2012) and his leadership team.

That said, I wouldn’t buy the stock today. This is only because my wife and I already have large sums invested in FTSE 100 index trackers. And remember that AstraZeneca accounts for almost 9% of the entire Footsie. Hence, my family already has a decent stake in this great British business!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Cliff D'Arcy has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services, such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool, we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 shares I’d buy for passive income if I was retiring early

Roland Head profiles three FTSE 350 dividend shares he’d like to buy for their passive income to support an early…

Read more »

Investing Articles

Here’s how many Aviva shares I’d need for £1,000 a year in passive income

Our writer has been buying shares of this FTSE 100 insurer, but how many would he need to aim for…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With an £8K lump sum, I could create an annual second income worth £5,347

This Fool explains how a second income is achievable by using a lump sum, investing in stocks, and the magic…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BT share price in the next 3 years

With the BT share price down so low, the dividend looks very nice indeed. The company's debt is off-putting, though.…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

28% revenue growth per year and down over 20% in price! Should I invest in this niche FTSE 250 company?

Oliver says this FTSE 250 company has done an excellent job bringing auctioning into the modern world. Will he invest…

Read more »

Investing Articles

After gaining over 200% in 12 months, what’s next for Nvidia stock?

Oliver thinks Nvidia stock could be as enduring an investment as Amazon. Even given the valuation risks, he says he…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

With a 6.7% yield, I consider Verizon exceptional for passive income

Oliver Rodzianko says Verizon offers one of the best passive income opportunities on the market. He just needs to remember…

Read more »